Ingelheim/Germany, 26 January 2012 – Boehringer Ingelheim has expanded its biopharmaceutical cell line development services and provides drug substance as fast as 13 months at competitive prices. The novel program is called ‘Lean-to-Clinic’ and leverages Boehringer Ingelheim’s established platforms and processes for the production of monoclonal antibodies using the proprietary BI-HEX® high expression system.
Boehringer Ingelheim launches ‘Lean-to-Clinic’ program for fast drug product supply
Ingelheim/Germany, 26 January 2012 – Boehringer Ingelheim has expanded its biopharmaceutical cell line development services
Jan 26, 2012